Bottom line: Hong Kong’s IPO market will heat up in the first quarter of next year for non-financial Chinese offerings, while privatizations of Chinese firms from New York are likely to accelerate at raised offering prices.
Taomee, Wuxi Pharma join homeward migration
A series of new listings in Hong Kong and de-listings from New York are heating up the headlines as we head toward year-end, reflecting 2 of the major themes for 2015 IPOs. Hong Kong hasn’t exactly been a hotbed for new listings this year, but has been gaining recent momentum that includes news of a $300 million planned IPO by hotpot chain Haidilao. At the same time, other reports are saying that Bank of Zhengzhou has just launched its own Hong Kong IPO, spotlighting another trend that has seen a flurry of mainland Chinese banks try to tap the market to bolster their financially-stretched balance sheets.
Meantime across the Pacific in New York, children’s website Taomee (NYSE: TAOM) and drug maker Wuxi PharmaTech (NYSE: WX) have come closer to completing previously announced privatization plans, as part of a broader exodus of Chinese companies from the US. The former case has Taomee announcing it has formally signed a buyout deal to privatize the company, and Wuxi Pharma saying it has completed its own privatization. Read Full Post…
Bottom line: The ongoing privatization wave of Chinese firms abandoning New York listings is likely at or near a peak, with gaming and solar companies as some of the likeliest candidates to make new announcements.
E-House heads for exit door
The exodus from New York by neglected Chinese companies marches on this week, with online real estate company E-House (NYSE: EJ) becoming the latest to receive a management-led buyout offer. At the same time, online dating site Jiayuan (Nasdaq: DATE) has announced that a suitor who made a similar offer for the company in March has sharply raised its bid, following complaints that the original offer grossly undervalued the company.
When the history books are written, the second quarter of 2015 could well go down as the height of a wave of privatization bids for New York-listed Chinese firms, whose shares have languished in the last few years due to lack of interest from US investors. At the same time, many of those companies are casting an envious eye on China’s rallying stock markets, and are almost certainly hoping to re-list at home in the future. Read Full Post…
Bottom line: China’s securities regulator should work with overseas-listed Chinese firms to chart a well-defined path for them to return home to list, to encourage such movement and avoid burdensome bureaucracy.
Chinese “turtles” return home to list
A growing trend that is seeing Chinese firms abandon US listings to return home gained big momentum last week, when 2 more companies announced plans to de-list from New York and a third that privatized 2 years ago moved close to a China re-listing.
In the first category, medical devices maker Mindray Medical (NYSE: MR) announced a management led buy-out offer late in the week, which was followed a day later by a similar offer for solar panel maker JA Solar (Nasdaq: JASO). Meantime, formerly New York-listed outdoor advertising specialist Focus Media took a major step toward becoming the first Chinese company to re-list at home by injecting itself to an existing Shenzhen-traded company. Read Full Post…
Bottom line: Baozun’s IPO is likely to price in the middle of its range and debut flat despite its strong credentials, as waning sentiment towards Chinese Internet companies may prompt other recently listed names like Jumei to launch privatization bids.
Baozun IPO gets lukewarm response
Sentiment towards China-listed US firms continues to show signs of weakening, with word that e-commerce website designer Baozun has had to scale back its IPO in New York as its shares move closer to their trading debut. Meantime, shares have jumped over the last week for e-commerce firm Jumei International (NYSE: JMEI), amid talk that it may be considering a privatization bid to re-list back back in China.
Both stories reflect a recent trend that has seen a growing number of second-tier Chinese Internet companies abandon New York listings due to lack of investor interest. Many are believed to be eying re-listings in China, where their names are better known and companies of all types have achieved lofty valuations these days during a stock market surge that has seen shares double since a rally dating back to last summer. Read Full Post…
Bottom line: WuXi PharmaTech’s privatization will be followed by at least 3-4 more similar buy-outs this year for US-traded Chinese stocks, including a 50-50 chance that Renren will attempt a privatization by mid-year.
Wuxi Pharma gets buy-out bid
I’m beginning to feel like I should start a betting list of Chinese candidates that may de-list from New York, following word that unappreciated drug maker WuXi PharmaTech (NYSE: WX) has become the latest company to announce a management-led buy-out. At the same time, dying social networking (SNS) site Renren(NYSE: RENN) has also announced results of its own recent Dutch auction-style share buyback plan, which also hints that it could become the next company to attempt a privatization. Read Full Post…
The following press releases and media reports about Chinese companies were carried on May 1-4. To view a full article or story, click on the link next to the headline.
══════════════════════════════════════════════════════
Walmart (NYSE: WMT) To Boost Sam’s Club China Stores By 60 Pct Over 3 Years (Chinese article)
WuXi PharmaTech (NYSE: WX) Announces Receipt Of Buyout Proposal (PRNewswire)
Itochu, CP Group In E-commerce Venture With Chinese Firms In Shanghai FTZ (English article)
ZTE (HKEx: 763) Taps Japan To Help Sell 60 Mln Handsets Globally (English aritcle)
‘Cheating’ Chinese Antivirus Firm Qihoo 360 (NYSE: QIHU) Blames Cultural Differences (English article)
A few news bits and data points are spotlighting the big potential in China’s healthcare market over the next few years for companies that can tap into an overhaul of the national medical system. While that news looks good for healthcare companies overall, the limited universe of publicly traded firms available to western investors looks a bit spottier due to individual company issues. Regulatory issues could also be a risk, as highlighted by a new price fixing ruling against US drug giant Johnson & Johnson (NYSE: JJ). Still, there could be some interesting buying opportunities for the right companies. Read Full Post…
The following press releases and media reports about Chinese companies were carried on January 11-13. To view a full article or story, click on the link next to the headline.
══════════════════════════════════════════════════════
China’s Fosun (HKEx: 656) Picked To Buy Portugal Insurer In Privatization (English article)
VNO Users To Reach 50 Mln In 2015 – Regulator (English article)
US Judge Opens Way For China’s Wanxiang Bid For Fisker (English article)
Xiaomi To Roll Out Super Low-Cost 300 Yuan Smartphone In 2014 – Report (Chinese article)
The following press releases and media reports about Chinese companies were carried on December 19. To view a full article or story, click on the link next to the headline. ══════════════════════════════════════════════════════
Chinese Internet Users Reach 550 Mln – MIIT (Chinese article)
The following press releases and media reports about Chinese companies were carried on August 14. To view a full article or story, click on the link next to the headline. ══════════════════════════════════════════════════════
The following press releases and media reports about Chinese companies were carried on February 3. To view a full article or story, click on the link next to the headline.
